NexoBrid for Eschar Removal in Thermal Burns

On December 28,2022, the FDA granted approval to anacaulase-bcdb (NexoBrid) for eschar removal in adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.1 Current standard of care for DPT and/or FT burns includes excisional debridement and auto-grafting,2 which comes with risks of serious complications. The phase 3 DETECT clinical trial (NCT02148705) compared anacaulase-bcdb with standard of care (SOC) and gel placebo in a 3:3:1 ratio in adult patients with DPT and/or FT burns up to 30% total body surface area (TBSA) in a topical treatment period. Safety and effectiveness of anacaulase-bcdb has not been established in chemical or electric burns; burns on the face, perineum, or genitalia; feet burns of those with diabetes or those with occlusive vascular disease; circumferential burns; or burns in patients with significant cardiopulmonary disease including inhalation injury.